Theravance Biopharma, Inc.

TBPH· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$16.87+0.06%

2026-08-03

Financials

Valuation Metrics

Theravance Biopharma, Inc.'s Market Cap is $870M. At end of 2025 it was $952M. Ranked #2570 of 3,112 in US market (top 83%), #1072 of 1,445 on NASDAQ (top 74%), #199 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$870M	US#2,570/3,112 Sec#199/269
Revenue	$110M	US#2,768/3,112 Sec#123/269
Net Income	$115M	US#1,551/3,112 Sec#53/269
Total Assets	$472M	US#2,762/3,112 Sec#163/269
Net Assets	$291M	US#2,561/3,112 Sec#159/269
Value
P/E	7.59x	US#127/3,112 Sec#9/269
P/B	2.99x	US#1,672/3,112 Sec#87/269
P/S	7.92x	US#2,561/3,112 Sec#111/269
EV/EBITDA	4.60x	US#132/3,112 Sec#9/269
FCF Yield	30.90%	US#63/3,112 Sec#4/269
Profitability
ROE	39.42%	US#172/3,112 Sec#18/269
ROA	24.25%	US#49/3,112 Sec#12/269
Op. Margin	0.08%	US#2,413/3,112 Sec#88/269
Revenue Growth	15.02%	US#968/3,112 Sec#83/269
Financial Health
Debt Ratio	62.53%	US#695/3,112 Sec#149/269
Total Debt	$73M	US#2,461/3,112 Sec#134/269
FCF	$269M	US#1,202/3,112 Sec#40/269
Cash	$288M	US#1,466/3,112 Sec#85/269
Current Ratio	13.14x	US#185/3,112 Sec#62/269
Net Debt/EBITDA	-1.51x	US#235/3,112 Sec#18/269
Performance
1Y Return	54.77%	US#748/3,112 Sec#122/269
1M Return	-0.35%	US#1,701/3,112 Sec#80/269
From 52W High	-19.78%	US#1,713/3,112 Sec#109/269
1Y MDD	-34.57%	US#1,667/3,112 Sec#109/269
Trading
Volume	422,346 shares	US#2,183/3,112 Sec#213/269
Trading Value	$7M	US#2,519/3,112 Sec#203/269
Per Share
EPS	$2.08	US#1,241/3,112 Sec#41/269
BPS	$9.55	US#1,821/3,112 Sec#66/269